eligibility_summary
Eligibility: 18–75, ECOG 0–1, untreated locally advanced NPC (AJCC 2018 III–IVa: T3–4N2M0 or T1–4N3M0, WHO II/III), measurable lesion, ≥3‑mo survival, adequate counts and renal/hepatic function, neg pregnancy test. Exclude: recent RT/chemo/IO/immunosuppressants/EGFR‑TKI/anti‑VEGF (≤6 mo), other trials/major surgery ≤30 d, uncontrolled comorbidities, other cancer, IO contraindications (autoimmune, transplant, ILD, HIV/HBV/HCV, CNS mets), drug allergy, ≥G2 neuropathy/hearing loss, pregnancy/lactation, no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial of induction therapy combining GP (gemcitabine + cisplatin) with nimotuzumab and sintilimab for locally advanced nasopharyngeal carcinoma prior to chemoradiotherapy. Drugs and mechanisms: Gemcitabine (antimetabolite nucleoside analog) inhibits ribonucleotide reductase and incorporates into DNA to block synthesis, Cisplatin (platinum alkylating-like agent) forms DNA crosslinks causing DNA damage/apoptosis, Nimotuzumab (humanized anti-EGFR IgG1 mAb) blocks EGFR signaling and can mediate ADCC, Sintilimab (anti–PD-1 IgG4 mAb) blocks PD-1 on T cells to restore antitumor immunity. Targets/pathways: proliferating tumor cells (DNA synthesis/repair), EGFR-driven signaling in NPC cells, and the PD-1/PD-L1 immune checkpoint to activate cytotoxic T cells.